Grandfield & Dodd, LLC Intellia Therapeutics, Inc. Transaction History
Grandfield & Dodd, LLC
- $1.61 Billion
- Q2 2025
A detailed history of Grandfield & Dodd, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 48,705 shares of NTLA stock, worth $1.21 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
48,705
Previous 48,645
0.12%
Holding current value
$1.21 Million
Previous $345,000
32.17%
% of portfolio
0.03%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding NTLA
# of Institutions
334Shares Held
97MCall Options Held
1.66MPut Options Held
1.03M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$324 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$270 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$239 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.12MShares$103 Million0.0% of portfolio
-
State Street Corp Boston, MA4.04MShares$101 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.89B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...